Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Belimumab in SLE (LBSL99)
NCT00583362Phase 2Completed
- Sponsor
- GSK
- Start
- May 2005
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoints: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) up to 13 years, Adverse Event (AE) Rates by System Organ Class (SOC) During the Study up to 13 years and 4 more. Started May 2005; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00583362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00583362.